A VISIONaerie® approach
We discover, develop and commercialize first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases
News Highlights
Aerie Pharmaceuticals Receives Marketing Authorisation of Roclanda® 50 mic... Aerie Pharmaceuticals Announces Publication of Peer-Reviewed Paper Evaluati... Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financi...STOCK Quote
NASDAQ: AERI
$17.78USD
Apr 22, 4:00 PM ET
VOLUME
318,657
DAY LOW/HIGH
$17.43/$17.98
52 - WEEK LOW/HIGH
$9.01/$21.30
